Inhibrx Biosciences, Inc. (INBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has a cash flow conversion efficiency ratio of -3.769x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.12 Million) by net assets ($7.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Inhibrx Biosciences, Inc. (INBX) balance sheet quality index to measure how much of total assets are equity-financed.
Inhibrx Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Inhibrx Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INBX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Inhibrx Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bellring Brands LLC
NYSE:BRBR
|
0.022x |
|
Netcare
JSE:NTC
|
0.220x |
|
Abacus Storage King
AU:ASK
|
0.012x |
|
Shenzhen Minkave Technology Co Ltd
SHE:300506
|
0.013x |
|
Jupiter Wagons Limited
NSE:JWL
|
-0.041x |
|
MBB INDUSTRIES
XETRA:MBB
|
0.067x |
|
Arcadyan Technology Corp
TW:3596
|
0.320x |
|
Bk Harda Internasional Tbk Pt
JK:BBHI
|
0.052x |
Annual Cash Flow Conversion Efficiency for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Inhibrx Biosciences, Inc. from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see INBX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.99 Million | $-129.79 Million | -16.238x | -1015.79% |
| 2024-12-31 | $133.58 Million | $-194.41 Million | -1.455x | +67.25% |
| 2023-12-31 | $43.50 Million | $-193.31 Million | -4.444x | -123.75% |
| 2022-12-31 | $58.06 Million | $-115.30 Million | -1.986x | -29.52% |
| 2021-12-31 | $52.38 Million | $-80.32 Million | -1.533x | -141.26% |
| 2020-12-31 | $75.47 Million | $-47.97 Million | -0.636x | -285.38% |
| 2019-12-31 | $-93.57 Million | $-32.08 Million | 0.343x | -14.42% |
| 2018-12-31 | $-57.64 Million | $-23.09 Million | 0.401x | -52.10% |
| 2017-12-31 | $-22.42 Million | $-18.75 Million | 0.836x | +105.72% |
| 2016-12-31 | $1.24 Million | $-18.11 Million | -14.615x | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more